Forward-Looking Statements This presentation may also contain statistical data, estimates and/or other information or data made by independent parties and/or by us relating to market size and growth, as well about our industry and business. Any such data or information that is based on estimates, forecasts, projections, market research, or similar methodologies, involve a number of assumptions and limitations and are inherently subject to uncertainties, and we have not independently verified the accuracy or ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39577 Aziyo Biologics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdictio ...

Aziyo Biologics, Inc. (AZYO) Q1 2023 Earnings Conference Call May 10, 2023 4:30 PM ET Company Participants Matt Steinberg - Investor Relations Randy Mills - Chief Executive Officer Matt Ferguson - Chief Financial Officer Conference Call Participants Ross Osborn - Cantor Operator Good day, ladies and gentlemen. Welcome to the Aziyo Biologics First Quarter 2023 Financial Results Conference Call. [Operator Instructions] Please be advised that today’s conference call is being recorded. I would now like to hand ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39577 Aziyo Biologics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdicti ...

Aziyo Biologics, Inc. (AZYO) Q4 2022 Earnings Conference Call March 22, 2023 4:30 PM ET Company Participants Matt Steinberg - Investor Relations, FINN Partners Randy Mills - Chief Executive Officer Matt Ferguson - Chief Financial Officer Conference Call Participants Ross Osborn - Cantor Fitzgerald Josh Jennings - TD Cowen & Company Operator Good day, ladies and gentlemen, and welcome to the Aziyo Biologics Fourth Quarter and Full Year 2022 Financial Results Call. At this time, all participants are in a list ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2022 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For transition period from to Commission File Number: 001-39577 Aziyo Biologics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of inc ...

Aziyo Biologics, Inc. (AZYO) Q3 2022 Results Conference Call November 14, 2022 4:30 PM ET Company Participants Matt Steinberg - Fin Partners Randy Mills - CEO Matt Ferguson - CFO Conference Call Participants Josh Jennings - Cowen Simran Kaur - Piper Sandler David Rescott - Truist Securities Operator Good day, ladies and gentlemen, and thank you for standing by. Welcome to the Aziyo Biologics Third Quarter 2022 Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is bei ...

Table of Contents Title of each class Trading Symbol(s) Name of each exchange on which registered Class A Common Stock, par value $0.001 per share AZYO The Nasdaq Capital Market UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the ...

Risk Factors - The company is exposed to various risks, including the ability to enhance products and maintain relationships with contract manufacturing customers[8] - As of June 30, 2022, one customer represented 10% or more of the company's accounts receivable, indicating significant customer concentration risk[272] - The company does not currently engage in hedging transactions to manage interest rate risk, which is sensitive to changes in U.S. monetary policies[270] - Inflationary pressures may adversely affect operating results, although the company did not experience material impacts from inflation during the six months ended June 30, 2022[274] - The company is subject to regulatory approval risks from the U.S. FDA and comparable foreign authorities for its products[10] - The company acknowledges the potential adverse impacts of COVID-19 and other infectious diseases on its operations[8] Business Operations - The company remains an emerging growth company until annual gross revenues reach $1.07 billion or more, or until other specified conditions are met[278] - The company relies on commercial partners and independent sales agents for a substantial portion of net sales, highlighting dependence on third parties[8] - The company is focused on expanding its product offerings and market presence, which may involve new product development and acquisitions[8] Financial Stability - The company has not experienced material credit risk due to maintaining cash and cash equivalents with a single financial institution[271]

Aziyo Biologics, Inc. (AZYO) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Leigh Salvo - IR Kevin Rakin - Executive Chairman Randy Mills - CEO Matthew Ferguson - CFO Conference Call Participants Josh Jennings - Cowen David Rescott - Truist Ross Osborn - Cantor Fitzgerald Operator Good day. And thank you for standing by. Welcome to the Aziyo Biologics Second Quarter 2022 Earnings Conference Call. At this time, all participants are in listen-only mode. After the speaker's pr ...